FindTrial
Sign In

A randomized controlled study of topical use of plasma-activated hydropharyngeal in the treatment of patients with novel coronavirus pneumonia

A randomized controlled study of topical use of plasma-activated hydropharyngeal in the treatment of patients with novel coronavirus pneumonia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056562
Enrollment
Unknown
Registered
2022-02-08
Start date
2022-01-21
Completion date
Unknown
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Control group:Normal saline
Experimental group:Plasma active water

Sponsors

The First Affiliated Hospital of Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Mild and common SARS-CoV-infected adults with positive throat swab nucleic acid, with or without pharyngeal symptoms, and no basic diseases of liver, kidney, blood system and other important organs. 2. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: Minor patients <=14 years.

Design outcomes

Primary

MeasureTime frame
Detection of new coronal nucleic acid;—

Countries

China

Contacts

Public ContactSong Liqiang

The First Affiliated Hospital of Air Force Medical University

songlq@fmmu.edu.cn+86 13991160546

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026